Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program
Authors' conclusion
In this post hoc analysis, tirzepatide at all doses studied was associated with a greater reduction in the prevalence of patients meeting the criteria for metabolic syndrome compared to placebo, semaglutide 1 mg, insulin degludec, and insulin glargine. Although more evidence is needed, these data would support greater potential improvement in cardiovascular risk factor profile with tirzepatide treatment in people across the continuum of T2D.
Study context
- Population
- Patients with T2D in the SURPASS 1–5 trials
- Comparison
- Tirzepatide vs placebo, semaglutide 1 mg, insulin degludec and insulin glargine
- Primary endpoint
- Prevalence of patients meeting criteria for metabolic syndrome (≥ 3 of 5 NCEP ATP III criteria)
- Follow-up
- Primary endpoint of each trial
Methodological detailson-treatment data, patients adherent to treatment (taking ≥ 75% study drug), logistic regression adjusted for baseline metabolic syndrome status
- On-treatment data
- Patients adherent to treatment (taking ≥ 75% study drug)
- Logistic regression adjusted for baseline metabolic syndrome status
Primary result
As reported in the abstract
Prevalence of metabolic syndrome · primary endpoint
Tirzepatide
38-64%
P < 0.001
- Prevalence with comparators at primary endpoint
- 64-82%
- Prevalence at baseline across treatment groups
- 67-88%
Further findings
Individual components of metabolic syndrome
- Reduced to a greater extent with tirzepatide vs comparators
Prevalence by categorical weight loss
- Greater body weight reductions associated with greater reductions in metabolic syndrome prevalence and its components
Prevalence by background SGLT2i or SU use and gender
- Background SGLT2i or SU use or gender did not impact the change in prevalence
Original publication
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program. Cardiovasc Diabetol. Published 10 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →